Autopsy report · NCT04036461

A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“Slow accrual”

The sponsor’s own words in the registry.

Life of this trial

Registered 1 month before it started.
Ran for about 5 years before it stopped.
47 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 1
Sponsor: Celgene
Sponsor type: Industry
Conditions: Multiple Myeloma
Interventions: CC-99712; BMS-986405
Participants: 47
Sites: 20
Countries: Canada, France, Italy, Spain, United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.